Thrombolysis in stroke despite contraindications or warnings?

Stroke

Volumn 44, Issue 3, 2013, Pages 727-733

  Frank, Benedikt ^a,b   Grotta, James C ^c   Alexandrov, Andrei V ^d   Bluhmki, Erich ^e   Lyden, Patrick ^f   Meretoja, Atte ^g,h   Mishra, Nishant K ⁱ   Shuaib, Ashfaq ^j   Wahlgren, Nils G ^k   Weimar, Christian ^b   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d The University of Alabama at Birmingham   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF ALBERTA   (Canada)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Contraindications; Exclusion; Outcomes; Stroke management; Thrombolysis

Indexed keywords

ALTEPLASE; GLUCOSE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84876294536     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.674622     Document Type: Article

References (31)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-15877
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
5. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
6. Aleu A, Mellado P, Lichy C, Köhrmann M, Schellinger PD. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. 2007;38:417-422.
7. De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke. 2007;38:2612-2618.
8. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41:1450-1458.
9. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372.
10. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, et al. The Virtual International Stroke Trials Archive. Stroke. 2007;38:1905-1910.
11. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.
12. eMC. Actilyse: Summary of Product Characteristics. http://www. medicines.org.uk/emc/document.aspx?documentId=308. Accessed 19/04/2012.
13. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al.; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
14. Genentech. Activase: Full Prescribing Information. http://www.gene. com/gene/products/information/pdf/activase-prescribing.pdf. Accessed 26/04/2012.
15. Mishra NK, Lyden P, Grotta JC, Lees KR; VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010;41:2612-2617.
16. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR; VISTA Collaborators. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010;41:2840-2848.
17. Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke. 2010;41:2568-2574.
18. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al.; VISTA collaborators; SITS collaborators. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010;341:c6046.
19. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The strokethrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37: 2957-2962.
20. Mishra NK, Ahmed N, Davalos A, Iversen HK, Melo T, Soinne L, et al.; SITS and VISTA collaborators. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology. 2011;77:1866-1872.
21. Mishra NK, Davis SM, Kaste M, Lees KR; VISTA Collaboration. Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care. 2010;33:2531-2537.
22. Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41:288-294.
23. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363.
24. Ibrahim MM, Sebastian J, Hussain M, Al-Hussain F, Uchino K, Molina C, et al.; CLOTBUST Investigators. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen- activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis. 2010;30:508-513.
25. Brunner F, Tomandl B, Schröter A, Mellinghoff C, Haldenwanger A, Hildebrandt H, et al. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur J Neurol. 2011;18:1407-1411.
26. Prabhakaran S, Rivolta J, Vieira JR, Rincon F, Stillman J, Marshall RS, et al. Symptomatic intracerebral hemorrhage among eligible warfarintreated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010;67:559-563.
27. Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71:634-641.
28. Ahmed N, Dávalos A, Eriksson N, Ford GA, Glahn J, Hennerici M, et al.; SITS Investigators. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol. 2010;67:1123-1130.
29. Tsivgoulis G, Frey JL, Flaster M, Sharma VK, Lao AY, Hoover SL, et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. 2009;40:3631-3634.
30. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, et al.; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286: 2830-2838.
31. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al.; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.